BioAge Labs financials
$7.14−0.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $9.0M | $0.00 |
| Gross profit | $9.0M | $0.00 |
| Gross margin | 100.0% | — |
| Operating income | -$92.8M | -$78.2M |
| Net income | -$80.6M | -$71.1M |
| Net margin | −896.1% | — |
| Diluted EPS | $-2.24 | $-6.63 |
| EBITDA | -$92.6M | -$78.0M |
| Operating cash flow | -$81.6M | -$51.5M |
| Free cash flow | -$82.3M | -$51.9M |
| Diluted shares | 35.9M | 10.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $188.9M | $354.3M |
| Short-term investments | $92.2M | $0.00 |
| Total debt | $2.6M | $8.5M |
| Total assets | $294.9M | $358.2M |
| Total liabilities | $22.8M | $35.1M |
| Shareholders' equity | $272.1M | $323.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology